Verifying…
Home / Drug A–Z / Johnbee Fluconazole 200 mg Capsules

Johnbee Fluconazole 200 mg Capsules

NAFDAC Reg. No. C4-1596 · Drug

Registered with NAFDAC. Registration activeAs of 27 October 2026 · synced automatically from official sources.
Product
Johnbee Fluconazole 200 mg Capsules
NAFDAC number
C4-1596
Active ingredient
Fluconazole
Strength
200 mg
Form
Capsule
Pack size
10 x 10's (in strips)
Manufacturer
Not listed
Applicant (holder)
Eskay Nez Industries Limited
Approved
25 Feb 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
24 Feb 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Johnbee Fluconazole 200 mg Capsules is on the NAFDAC register with an active registration (C4-1596). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Johnbee Fluconazole 200 mg Capsules is used for

From the official U.S. FDA label for fluconazole, the active ingredient registered with NAFDAC.

What it is used for

Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis . Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis , please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. …

Possible side effects

Fluconazole is generally well tolerated. In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain. In Patients Receiving a Single Dose for Vaginal Candidiasis: During comparative clinical studies conducted in the United States, 448 patients with vaginal candidiasis were treated with fluconazole, 150 mg single dose. The overall incidence of side effects possibly related to fluconazole was 26%. …

Do not use if

Fluconazole tablets are contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. There is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole tablets to patients with hypersensitivity to other azoles. …

Warnings

(1) Hepatic injury: Fluconazole should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions. In cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex, or age of the patient has been observed. Fluconazole hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more severe hepatic injury. …

Pregnancy & breastfeeding

Pregnancy Teratogenic Effects Potential for Fetal Harm: Use in pregnancy should be avoided except in patients with severe or potentially life-threatening fungal infections in whom fluconazole may be used if the anticipated benefit outweighs the possible risk to the fetus. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Johnbee Fluconazole 200 mg Capsules

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Johnbee Fluconazole 200 mg Capsules

What is in Johnbee Fluconazole 200 mg Capsules?

Johnbee Fluconazole 200 mg Capsules contains Fluconazole (200 mg), as capsule, according to its NAFDAC registration record.

Is Johnbee Fluconazole 200 mg Capsules registered with NAFDAC?

Yes. Johnbee Fluconazole 200 mg Capsules is listed on the NAFDAC register under registration number C4-1596, and its registration is active as of 27 October 2026.

Has Johnbee Fluconazole 200 mg Capsules been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Johnbee Fluconazole 200 mg Capsules in our automatically synced alert list.

How can I check that my pack of Johnbee Fluconazole 200 mg Capsules is genuine?

Run a free authenticity scan with the NAFDAC number C4-1596, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Johnbee Fluconazole 200 mg Capsules used for?

Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, diss (Summarised from the official U.S. FDA label for fluconazole. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Johnbee Fluconazole 200 mg Capsules? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.